Treatment Options for Hodgkin’s Lymphoma

Hodgkin's disease is a relatively rare form of lymphoma, a kind of cancer that affects B- and T-cell lymphocytes. These cells play a vital role in the immune system, but the cancer causes them to rapidly grow out of control. Because the lymphatic system is so extensive, lymphoma can easily spread to other areas of the body, making treatment difficult. Nevertheless, both Hodgkin's and non-Hodgkin's lymphomas generally respond well to treatment if detected early.

Choices of treatment and the success of treatment will depend on a number of factors, including the patient's health, medical history, and age. The most important factor, though, will be the extent of the disease in the body, called its staging. The recommended treatment options for Hodgkin's lymphoma will vary based on this staging, which is typically represented by a scale of I to IV.

Stages I and II

If the cancer is detected on only one side of the diaphragm, treatment will depend on whether there are any unfavorable factors. These include the following:

  • Bulky growths
  • Multinodal (occurring in several locations)
  • Fever
  • Night sweats
  • Weight loss

Favorable

If the diagnosis is favorable, the most common Hodgkin's treatment is chemotherapy, administered as two to four cycles of the ABVD regimen or eight weeks of the Stanford V regimen. This is followed by local radiation therapy at the site of the disease. An oncologist will usually order a PET/CT scan following treatment to assess the efficacy of the protocol, at which point additional steps might need to be taken

Unfavorable

For cases that involve unfavorable factors, the chemotherapy dosages may be increased to four to six cycles of ABVD or 12 weeks of Stanford V, again followed by radiation and a PET/CT scan.

Stages III and IV

At these stages, the best treatment option for Hodgkin's lymphoma is chemotherapy at full doses (ABVD for 6 or more cycles or 12 weeks of Stanford V). In the most severe instances, a doctor may order the BEACOPP regimen. If this is unsuccessful, the doctor may recommend a stem cell transplant.

Resistance and Recurrence

The goal of treatment, in any stage, is the complete removal of all cancerous cells. In followup tests, the doctor will look for any sign that such cells remain in the body. If they do, it is generally accepted that the disease will not respond to more of the same treatment. Instead, oncologists typically suggest a different combination of chemotherapy drugs or localized radiation treatments if such treatments had not already been tried. Radiation cannot be applied to the same area twice, no matter how much time passes between treatments. Stem cell transplants—either autologous (using one's own cells) or allogenic (using donor cells)—are usually the final option, in cases where no other treatment has proven effective.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap